Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy
Our <i>in vitro</i> studies suggest the potential use of mRNA CD117 CAR T cells as a non-genotoxic preconditioning strategy for patients with high-risk or refractory AML.
Authors
- Koramit Suppipat (ORCID: https://orcid.org/0000-0002-4010-933X)
- Supannikar Tawinwung (ORCID: https://orcid.org/0000-0003-2151-4580)
- Thananya Inthanachai
- Chutamath Sittplangkoon (ORCID: https://orcid.org/0000-0002-9962-1899)
- Haruko Tashiro
- Shigeki Yagyu
Institutions
- Shinshu University (JP)
- Chulalongkorn University (TH)
- Government of Thailand (TH)
- Bangkok University (TH)
- Teikyo University (JP)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1016/j.iotech.2026.101584
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chulalongkorn University
- National Research Council of Thailand
- Thailand Science Research and Innovation